Literature DB >> 1381585

Lipoprotein (a) promotes plasmin inhibition by alpha 2-antiplasmin.

J M Edelberg1, S V Pizzo.   

Abstract

Plasmin inhibition by alpha 2-antiplasmin (alpha 2AP) is regulated by the vascular components fibrin(ogen) fragments, plasminogen and lipoprotein (a). Kinetic analysis demonstrates that CNBr-derived fibrinogen fragments completely protect plasmin from alpha 2AP. Plasminogen and 6-aminohexanoic acid decrease the rate of inhibition by 5- and 10-fold respectively. These studies show that CNBr-derived fibrinogen fragments and 6-aminohexanoic acid bind plasmin kringle(s) with binding constants of 2 micrograms/ml and 120 microM respectively, and that plasminogen binds to alpha 2AP with an affinity of 0.5 nM. The unmodulated inhibition is not effected by the presence of lipoprotein (a), but in the presence of protective CNBr-derived fibrinogen fragments the rate of inhibition is increased by the presence of the lipoprotein. The kinetics demonstrate that lipoprotein (a) binds to CNBr-derived fibrinogen fragments with an affinity of 4 nM, displacing plasmin from the protective surface. In addition, tissue-type plasminogen activator and trypsin inhibition by alpha 2AP is not slowed by the presence of CNBr-derived fibrinogen fragments or plasminogen (Pg), respectively. These kinetics suggest that the initial reversible interaction between plasmin and alpha 2AP is mediated by binding of the inhibitor to the kringle 1 domain of plasmin, with a reversible inhibition constant (Ki) of 5.0 x 10(-10) M. Under conditions where this kringle-inhibitor interaction is blocked, the reversible inhibition still occurs between the plasmin and alpha 2AP, but the initial Ki is increased to 5.0 x 10(-9) M. These data suggest that, in the circulation, plasmin inhibition by alpha 2AP may be down-regulated by fibrin, fibrin(ogen) fragments and Pg, but up-regulated by lipoprotein (a) in the presence of fibrin or fibrin(ogen) fragments. The lipoprotein (a)-mediated promotion of plasmin inhibition may provide an additional mechanism by which the lipoprotein impairs fibrinolysis and promotes atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381585      PMCID: PMC1133020          DOI: 10.1042/bj2860079

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

1.  p-Nitrophenyl-p'-guanidinobenzoate HCl: a new active site titrant for trypsin.

Authors:  T Chase; E Shaw
Journal:  Biochem Biophys Res Commun       Date:  1967-11-30       Impact factor: 3.575

2.  Binding site of alpha 2-plasmin inhibitor to plasminogen.

Authors:  N Sugiyama; T Sasaki; M Iwamoto; Y Abiko
Journal:  Biochim Biophys Acta       Date:  1988-01-04

3.  Autonomous functions of structural domains on human tissue-type plasminogen activator.

Authors:  A J van Zonneveld; H Veerman; H Pannekoek
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.

Authors:  J W McLean; J E Tomlinson; W J Kuang; D L Eaton; E Y Chen; G M Fless; A M Scanu; R M Lawn
Journal:  Nature       Date:  1987 Nov 12-18       Impact factor: 49.962

5.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

Authors:  M Hoylaerts; D C Rijken; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

6.  Properties of three different molecular forms of the alpha 2 plasmin inhibitor.

Authors:  I Clemmensen; S Thorsen; S Müllertz; L C Petersen
Journal:  Eur J Biochem       Date:  1981-11

7.  Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen.

Authors:  D L Eaton; G M Fless; W J Kohr; J W McLean; Q T Xu; C G Miller; R M Lawn; A M Scanu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2.

Authors:  W Nieuwenhuizen; J H Verheijen; A Vermond; G T Chang
Journal:  Biochim Biophys Acta       Date:  1983-02-22

9.  Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.

Authors:  P C Harpel; T S Chang; E Verderber
Journal:  J Biol Chem       Date:  1985-04-10       Impact factor: 5.157

10.  Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin.

Authors:  J H Verheijen; M P Caspers; G T Chang; G A de Munk; P H Pouwels; B E Enger-Valk
Journal:  EMBO J       Date:  1986-12-20       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.